RU2061482C1 - Method of rheumatic arthritis treatment - Google Patents

Abstract

FIELD: medicine, rheumatology. SUBSTANCE: method involves the administration of voltaren (dose is 75 mg/24 h, every day) and additional administration of papaverine (dose is 80 mg/24 h) in combination with electrophoresis using 2% papaverine solution on the damaged joints for 14-21 days. EFFECT: prolonged remission of disease, decreased treatment time. 2 tbl

Description

 The invention relates to medicine, namely to rheumatology.

A known method of treating rheumatoid arthritis, including the introduction of non-steroidal anti-inflammatory drugs, in particular voltaren, in therapeutic doses [1]
However, to achieve the clinical effect, non-steroidal anti-inflammatory drugs (NSAIDs) must be used for a long time (months, years).

 The aim of the invention is to reduce the time of inpatient treatment and lengthening clinical remission.

 This goal is achieved by the combined use of voltaren and papaverine parenterally and by additional electrophoresis with a 2% solution of papaverine on the affected joints.

 The method is carried out by appointing patients with rheumatoid arthritis (RA) according to the developed scheme of voltaren at a dose of 75 mg / day and papaverine at a dose of 80 mg / day by injection daily and electrophoresis with 2% papaverine solution on the affected joints for 14-21 days.

 The therapeutic effect of the proposed method is shown in RA patients with RA. The data obtained are summarized in tables 1 and 2, differences in indicators are obtained at P <0.05 according to the criterion of Student.

Note to table 1: ^* differences in indicators are significant. As can be seen from the table. According to the data of the group of patients with RA treated with the combined effect of voltaren and papaverine, more pronounced shifts in the general clinical indicators of the process activity were noted: in addition to the ESR, α ₂ globulin and morning stiffness, significant dynamics were also noted in tests such as the articular index, the number of inflamed joints, and density heat flow.

 We have analyzed the dynamics of general clinical indicators of process activity on the 7th, 14th and 21st days of treatment. These data are presented in table 2. As you can see, a clear positive shifts in a number of tests of the activity of the process noted by the 14th day of treatment. This ultimately affected the length of stay of patients of both groups in the hospital and subsequently on the terms of clinical remission.

 We present the clinical observation of the use of both treatment complexes in the same patient with RA during two cycles of inpatient treatment.

Example 1. Patient T.O. 46 pet, medical history N 01/05446. He was treated in the rheumatology department of the Ternopil Regional Clinical Hospital from 4.O9 to 09.29.1989 with a diagnosis of RA, polyarthritis, seronegative, activity of the II degree, II stage, slowly progressing course, the Federal Tax Service of II degree. An objective examination showed signs of damage (configuration and deformation) of the ankle, knee, wrist and interphalangeal joints of the hands with a range of motion of 10% to 40%. Morning stiffness 60-90 minutes, articular index 8, the number of inflamed joints 3, painful 8, CRP - ++, ESR- 48 mm / h, α ₂ globulin 11.2% γ globulin 24% heat flux in the knee joints 260 • 10 ^-4 W / cm ² (control 150 • 10 ^-4 W / cm ² ) , wrist band 250 • 10 ^-4 W / cm ² (control 148 • 10 ^-4 W / cm ² ). Treatment: salazopyridazine 2 g / day), voltaren (75 mg / day), vitamin E (100 mg / day), retabolil, massage. Clinical improvement was noted in patients from day 9 of treatment. Research data during graduation: Morning stiffness 30-45 minutes, articular index 6, the number of inflamed joints no, the number of painful joints 6, CRP- +, ESR 30 mm / h, a ₂ -globulin 10.5% γ-globulin 22% density heat flow in the area of the knee joints 200. 10 ^-4 , wrist 190 • 10 ^-4 W / cm ² . The same patient (medical history N 01/06852) was hospitalized in the rheumatology department of the Termopol Regional Clinical Hospital from 10/15 to 11/11/1990 with the above diagnosis. Research data: Morning stiffness 60-75 minutes, articular index-7, number of inflamed joints 4, painful 9, CRP - ++, ESR 40 mm / h, a ₂ -globulin - 11% γ-globulin 23% heat flux in the area of the knee joints 255 • 10 ^-4 , wrist 258 • 10 ^-4 W / cm ² . Treatment: voltaren (75 mg / day), vitamin E (100 mg / day), retabolil, massage, papaverine (80 mg / day), electrophoresis with 2% papaverine solution alternately on the knee and wrist joints. Clinical improvement was noted in patients from day 6 of treatment. On discharge: Morning stiffness for 15-25 minutes, articular index 5, no inflamed joints, painful 3, CRP - +, ESR 25 mm / h, a ₂ -globulin 10% γ-globulin 22% heat flux in the knee joints 178 • 10 ^-4 , wrist 155 • 10 ^-4 W / cm ² . Thus, the combined use of voltaren and papaverine parenterally and papaverine in the form of a 2% solution for electrophoresis on the affected joints leads to faster positive dynamics of general clinical signs of activity of the process, which reduces the length of hospital stay of patients compared to the prototype from 21 to 18 days and lengthens clinical remission of the disease. TTT1 TTT2

Claims (1)

 A method of treating rheumatoid arthritis, including the introduction of voltaren, characterized in that in order to reduce treatment time and prolong clinical remission, voltaren is administered daily at a dose of 75 mg / day, papaverine is additionally administered at a dose of 80 mg / day and electrophoresis is carried out with a 2% solution papaverine on the affected joints for 14-21 days.

Images